The net proceeds to Sangamo from the sale of shares in this offering, after deducting underwriting discounts and commissions and other estimated offering expenses, were approximately $20.9 million.

Sangamo intends to use the net proceeds from the offering for working capital and other general corporate purposes, including support for the company's continuing R&D of its ZFP Therapeutic product candidates. Jefferies & Company acted as sole book-running manager in this offering.

A service of YellowBrix, Inc.